Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody

Immunotherapy

Volumn 4, Issue 3, 2012, Pages 335-343

  Norman, Andrew B ^a   Ball, William J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

addiction; cocaine; drug abuse; immunotherapy; monoclonal antibody; relapse prevention; vaccine

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALEMTUZUMAB; BASILIXIMAB; CHIMERIC ANTIBODY; COCAINE; DIGOXIN ANTIBODY F(AB) FRAGMENT; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY 2E2; OKT 3; TGN 1412; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANAPHYLACTIC SHOCK; CARDIOTOXICITY; COCAINE DEPENDENCE; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; CYTOLYSIS; DRUG ABUSE; DRUG EFFICACY; DRUG USE; HISTOPLASMOSIS; HUMAN; HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TUBERCULOSIS;

EID: 84858309119     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.19     Document Type: Review

References (33)

1. Kosten TR, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol. Ther. 108, 76-85 (2005). (Pubitemid 41377120)
2. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry 58, 158-164 (2005). (Pubitemid 41008133)
3. Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone maintained patients. Arch. Gen. Psychiatry 66(10), 1116-1123 (2009).
4. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry 67, 59-65 (2010).
5. Paula S, Tabet MR, Farr CD, Norman AB, Ball WJ. Modeling of cocaine binding by a novel human monoclonal antibody. J. Med. Chem. 47, 133-142 (2004).
6. Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 23, 1117-1125 (2005). (Pubitemid 41486393)
7. Harris DS, Everhart ET, Mendelson J, Jones RT. The pharmacology of cocaethylene in humans following cocaine and ethanol administration. Drug Alcohol Depend. 72, 169-182 (2003). (Pubitemid 37434009)
8. Norman AB, Tabet MR, Norman MK, Buesing WR, Pesce AJ, Ball WJ. A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J. Pharmacol. Exp. Ther. 320, 145-153 (2007). (Pubitemid 46025729)
9. Norman AB, Norman MK, Buesing WR, Tabet MR, Tsibulsky VL, Ball WJ. The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 328, 873-881 (2009).
10. Brimijoin S, Gao Y. Lasting reduction of cocaine action in neostriatum - a hydrolase gene therapy approach. J. Pharmacol. Exp. Ther. 330, 449-457 (2009).
11. Carroll ME, Gao Y, Brimijoin S, Anker JJ. Effect of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats. Psychopharmacology 213, 817-829 (2011).
12. Norman AB, Welge JA, Tsibulsky VL. Characterization of the distribution of the cocaine priming threshold and the effect of SCH23390. Brain Res. 946, 253-261 (2002). (Pubitemid 34876338)
13. Tsibulsky VL, Norman AB. Satiety threshold: a quantitative model of maintained cocaine self-administration. Brain Res. 839, 85-93 (1999). (Pubitemid 29389796)
14. Norman AB, Tsibulsky VL. The compulsion zone: a pharmacological theory of acquired cocaine self-administration. Brain Res. 1116, 143-152 (2006). (Pubitemid 44485005)
15. Norman AB, Norman MK, Tabet MR, Tsibulsky VL, Pesce AJ. Competitive dopamine receptor antagonists increase the equiactive cocaine concentration during self-administration. Synapse 65, 404-411 (2011).
16. Baud FJ, Borron SW, Scherrmann JM, Bismuth C. A critical review of antidotal immunotherapy for low molecular weight toxins. Arch. Toxicol. Suppl. 19, 271-287 (1997).
17. Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin. Pharmacokinet. 28, 483-493 (1995).
18. Baud F, Sabouraud A, Vicaut E, et al. Treatment of severe colchicine overdose with colchicine specific Fab fragments. N. Engl. J. Med. 332, 642-645 (1995).
19. Bowden CA, Krenzelok EP. Clinical applications of commonly used contemporary antidotes. Drug Safety 16(1), 9-47 (1997). (Pubitemid 27052876)
20. Gammagard Liquid®. In: Physicians' Desk Reference (61st Edition). Thomson PDR, Montvale, NJ, USA, 721-724 (2007).
21. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513-533 (2008). (Pubitemid 351600384)
22. Kohler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6(7), 511-519 (1976).
23. Cosimi AB. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Tranplantation 32(6), 535-539 (1981). (Pubitemid 12204717)
24. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human monoclonal antibodies from mice comprising four distinct genetic modifications. Nature 368, 856-859 (1994). (Pubitemid 24137750)
25. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nature Genet. 7, 13-21 (1994). (Pubitemid 24232374)
26. Marks JD, Hoogenboom HR, Bonnert TP, et al. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581-597 (1991).
27. Hansel TT, Kropshofer, S, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9, 325-338 (2010).
28. Hai SH, McMurray JA, Knopf PM, Martin W, De Groot AS. Immunogenicity screening using in silico methods. In: Therapeutic Monoclonal Antibodies: From Bench to Clinic. An Z (Ed.). John Wiley & Sons, Inc., Hoboken, NJ, USA, 417-437 (2009).
29. Gibson CR, Sandhu P, Hanley WD. Monoclonal antibody pharmacokinetics and pharmacodynamics. In: Therapeutic Monoclonal Antibodies: From Bench to Clinic. An Z (Ed.). John Wiley & Sons, Inc., Hoboken, NJ, USA, 439-460 (2009).
30. Van Walle I, Gansemans Y, Parren PW, et al. Immunogenicity screening in protein drug development. Expert Opin Biol. Ther. 7, 405-418 (2007). (Pubitemid 46383483)
31. 4+ effector memory T-cells. Br. J. Pharmacol. 161, 512-526 (2010).
32. Fishwild DM, O'Donnell SL, Bengoechea T, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14, 845-851 (1996). (Pubitemid 26239182)
33. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93(11), 2645-2668 (2004). (Pubitemid 39506617)